What is TAK's P/E ratio?

Takeda Pharmaceutical Co LTD ADR (TAK) currently trades at a P/E ratio of 0.27.

Takeda Pharmaceutical Co LTD ADR reports a Return on Equity (ROE) of 2.41%.

What is TAK's dividend yield?

Takeda Pharmaceutical Co LTD ADR offers a dividend yield of 3.47%.

What is TAK's Quality Score?

Our AI rates TAK's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TAK?

Our AI Timing Score for TAK is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TAK belong to?

Takeda Pharmaceutical Co LTD ADR is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE exchange

Takeda Pharmaceutical Co LTD ADR (TAK) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

TAK AI Analysis Summary

Our AI summary for TAK: Takeda Pharmaceutical Co LTD ADR (NYSE), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.27, ROE of 2.41%, a dividend yield of 3.47%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TAK

Takeda Pharmaceutical Co LTD ADR

USD 17.09

-0.16 (-0.93%) Day Change

Watchlist Portfolio Compare Chart

0.27

P/E

0.58

D/E

2.4%

ROE

1.2%

ROA

3.47%

Div Yield

0.11

PEG

TAKEDA PHARMACEUTICAL CO LTD ADR
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 17.09 Price -0.16 (-0.93%) Day Change	NEWS SCORE: 93

TAK, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

52%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	1079
Magic Formula Rank by ROE	1079
Magic Formula Rank by ROIC	770
Price	17.09
PBV / Sector	0.01 / 3.22 GREAT
Earning Per Share	56.51

PE / Sector	0.27 / 29.79 GREAT
PEG or PE/Growth / Sector	0.11 / 0.13 GREAT
Average 1M Daily Value	64.31 M
Average 1W Daily Value	77.99 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

58%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	3.91 / 15.21
NPM Average (%) / Sector	4.35 / -10.83
NPM Change Average (%) / Sector	-3.72 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	1.16 / 8.15
ROA Average (%) / Sector	1.29 / 2.87
ROA Change Average (%) / Sector	-4.22 / 112.70
ROE (%) / Sector	2.41 / -1.02
ROE Average (%) / Sector	2.71 / 8.35
ROE Change Average (%) / Sector	-5.46 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

62%

Dividend (%) / Sector	3.47 / 0.51 GOOD
Dividend Average (%) / Sector	3.76 / 3.06
Dividend Change Average (%) / Sector	13.21 / 13.64 GOOD

Registration Details

Analyze Date	2026-08-01 08:00:33
Symbol	TAK
Name	TAKEDA PHARMACEUTICAL CO LTD ADR
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NYSE
Listed Shares	3,193.50 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	55,087.93 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan, 103-8668

Phone: 81 3 3278 2111

Website: https://www.takeda.com

Employees: 47,029

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.